Navigation Links
De nouvelles directives recommandent la fidaxomicine pour tous les patients pouvant suivre un traitement antibiotique par voie orale pour une infection à Clostridium difficile
Date:10/29/2013

demiological Commentary: Mandatory MRSA, MSSA and E. coli bacteraemia, and C. difficile infection data (up to April-June 2013). 12 September 2013. Disponible en consultant : http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139835857 (dernière consultation 23 octobre 2013).

2. Meyer E et al. Associations between nosocomial meticillin-resistant Staphylococcus aureus and nosocomial Clostridium difficile-associated diarrhoea in 89 German hospitals. J Hosp Infect 2012;82(3):181-6.

3. Debast SB et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. doi: 10.1111/1469-0691.12418.

4. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.

5. Oake N, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010;170:1804-10.

6. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16.

7. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205.

8. Bouza E et al. Presented at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona 2008. Abstract0464.

9. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.

10. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N
'/>"/>

SOURCE Astellas Pharma Europe Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Medicare Procurement Program Creates Extreme Hardships For North Carolina Patients, Says AAHomecare
2. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
3. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
4. 3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Medicare Procurement Program Creates Extreme Hardships for Patients without Options, Says AAHomecare
7. Media Sourcerys Secure Mobile Workflow App Deployed by CCS Medical to Expedite Product Delivery to Patients
8. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
11. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /CNW/ -   ... after Health Canada tests confirmed it contains two undeclared ... and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... from retail stores across Canada . ... for weight loss and increased energy. ...
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
(Date:12/25/2014)... 2014 Parker & Sons, Inc. an ... and affordable quality regarding heating, cooling and plumbing services ... 2014 by the “Queen of Clean” for impressive contractor ... impressive reputation over the years for providing outstanding quality ... of contractor services for both homeowners and businesses. Linda ...
(Date:12/24/2014)... 25, 2014 AlignLife of Wauwatosa ... afford certain items. During the holiday season, AlignLife looks forward ... 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It ... joy, knowing that we are able to give kids toys ... not been for the generosity of our patients." , The ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife clinics ... smiling little faces this holiday that might not have ... donations was given to the various charities as well ... through the year. Some of the charities chosen for ... Shrine's Children's Hospitals, Toys for Tots and Crisis Nurseries, ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... 2014 Connie Casad, MD, a well-known ... advocate with 30 years of practice experience in Dallas, ... health benefits of dietary detoxification. The second study is ... excellent results from test patients who just completed a ... her interest in conducting the study, Dr. Casad said, ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... business response to global economic and social challengesNEW YORK, April ... aimed at creating new partnerships with governments, NGOs and small ... on Creating Shared Value in New York ... and the Mission of ...
... Inc. (OTC Bulletin Board: PLCSF) announced today that it expects ... the first quarter ended March 31, 2009 before the market ... host a conference call to discuss those results at 11:00 ... joined via telephone by dialing (866) 825-1708 or (617) 213-8060 ...
... 27 Cornerstone Therapeutics Inc. (NasdaqCM: CRTX), a specialty ... for respiratory disorders, today announced that it will host ... May 7, 2009, to discuss its financial results for ... also provide an update on the Company,s strategy, operations ...
... TERI, Inc., a national leader ... with autism and other developmental disabilities, today announced ... Quality Plans(TM) for families and caregivers of people ... the TERI-led International Association for Life Quality ( ...
... Group at Frost & Sullivan is pleased ... the Pharmaceutical CRM Market to be held on Tuesday, ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )2008 has ushered in a variety of ... is adopting a cautious approach, delaying and re-evaluating technology ...
... to highlight advances for chronic condition; third FDA-approved drug to come ... ... Each new treatment that becomes available is a step forward for ... National Fibromyalgia Association (NFA), which is observing Fibromyalgia Awareness ...
Cached Medicine News:Health News:Nestle Launches Major Initiatives in Nutrition, Water and Rural Development 2Health News:Nestle Launches Major Initiatives in Nutrition, Water and Rural Development 3Health News:Nestle Launches Major Initiatives in Nutrition, Water and Rural Development 4Health News:Cornerstone Therapeutics to Host First Quarter 2009 Conference Call 2Health News:Cornerstone Therapeutics to Host First Quarter 2009 Conference Call 3Health News:Cornerstone Therapeutics to Host First Quarter 2009 Conference Call 4Health News:TERI Offers Comprehensive Life Quality Plans to Families, Caregivers of People with Developmental Disabilities 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 2Health News:Frost & Sullivan: The Pharmaceutical Customer Relationship Management Market - What are the Emerging Trends and Opportunities? 3Health News:Treatment Options Increase For Millions with Fibromyalgia 2Health News:Treatment Options Increase For Millions with Fibromyalgia 3
... are problem enough for your patients. Now you ... functional treatment for foot and ankle fractures and ... A combination of prefabricated brace and open foam ... higher standards of safety. The storm can be ...
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... Bledsoe Mid-Calf Boot is a shorter ... boot designed for second degree ankle ... incision protection. The Bledsoe EZ Set ... of motion from 20 degrees of ...
... The Bledsoe Conformer Diabetic Boot features ... cocoon attached to a unique auto-molding innersole ... mid-sole insert in an aluminum shelled walking ... is designed to evenly distribute body weight ...
Medicine Products: